Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure

Details

Serval ID
serval:BIB_15865B9DE7B8
Type
Article: article from journal or magazin.
Collection
Publications
Title
Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure
Journal
Ann Surg Oncol
Author(s)
Boige V., Malka D., Elias D., Castaing M., De Baere T., Goere D., Dromain C., Pocard M., Ducreux M.
ISSN-L
1534-4681 (Electronic)1068-9265 (Linking)
Publication state
Published
Issued date
2008
Peer-reviewed
Oui
Volume
15
Number
1
Pages
219-26
Language
english
Notes
Boige, ValerieMalka, DavidElias, DominiqueCastaing, MarineDe Baere, ThierryGoere, DianeDromain, ClarissePocard, MarcDucreux, MichelengResearch Support, Non-U.S. Gov't2007/09/27 09:00Ann Surg Oncol. 2008 Jan;15(1):219-26. Epub 2007 Sep 26.
Abstract
BACKGROUND: We have previously shown promising activity of hepatic arterial infusion (HAI) oxaliplatin combined with intravenous (IV) 5-fluorouracil (5-FU) and leucovorin (LV) as first-line chemotherapy in patients with colorectal liver metastases (CRLM) (intent-to-treat [ITT] objective response rate [ORR], 64%; secondary resection rate, 18%; overall survival [OS], 27 months). Whether this regimen could be beneficial after systemic chemotherapy failure is unknown. METHODS: Patients with unresectable CRLM and history of systemic chemotherapy failure were treated bimonthly with HAI oxaliplatin (100 mg/m(2) 2 hours) combined with IV LV and IV bolus and infusional 5FU (modified LV5FU2 regimen). RESULTS: Forty-four consecutive patients (median age 56 years; median number of prior systemic chemotherapy regimens, 2 range 1-5) were included, of whom 43 (98%) had previously received oxaliplatin (n = 34), irinotecan (n = 37), or both (n = 28). Patients received a median of nine cycles of HAI oxaliplatin and IV modified LV5FU2 (range 0-25). Toxicity included grade 3-4 neutropenia (43%), grade 2-3 neuropathy (43%), and grade 3-4 abdominal pain (14%). We observed 24 partial ORs (62%) among the 39 assessable patients (ITT ORR, 55%; 95% CI, 40-69%), including 17, 12, and 12 patients who had failed to respond to prior systemic chemotherapy with FOLFIRI, FOLFOX, or both, respectively. Tumor response allowed further R0 surgical resection (n = 7) or radiofrequency ablation (n = 1) of initially unresectable CRLM in eight patients (18%). Median progression-free survival and OS were 7 and 16 months, respectively. CONCLUSIONS: HAI oxaliplatin and IV LV5FU2 is feasible, safe, and shows promising activity after systemic chemotherapy failure, allowing surgical resection of initially unresectable CRLM in 18% of patients.
Keywords
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage, Colorectal Neoplasms/*drug therapy/pathology, Feasibility Studies, Female, Fluorouracil/administration & dosage, Follow-Up Studies, *Hepatic Artery, Humans, Infusions, Intra-Arterial, Infusions, Intravenous, Leucovorin/administration & dosage, Liver Neoplasms/*drug therapy/secondary, Male, Middle Aged, Organoplatinum Compounds/administration & dosage, Prospective Studies, Survival Rate, Treatment Outcome
Create date
16/09/2016 11:13
Last modification date
20/08/2019 13:44
Usage data